Last updated: February 22, 2026
What does the scope of HK patent HK1219457 cover?
Patent HK1219457 relates to a pharmaceutical invention. The patent’s documentation indicates that its scope covers specific chemical compounds, formulations, and methods for therapeutic use. Its central claim involves a new class of compounds with potential applications in treating certain diseases.
Key aspects of the patent scope include:
- Specific chemical structures: The patent claims involve compounds defined by a core structure with particular substituents, precise in chemical nomenclature.
- Formulation aspects: Claims extend to pharmaceutical compositions containing the claimed compounds.
- Therapeutic methods: Claims include methods for treating diseases using these compounds.
The patent's scope is relatively narrow, focusing on particular chemical derivatives and their application, which limits its coverage to those specific compounds and methods.
What are the primary claims of HK1219457?
HK1219457 contains several claims, primarily categorized as:
-
Compound Claims: Covering the chemical entities with defined structural features. For example:
- A compound with a core structure represented by formula X, where R1 and R2 are specific substituents, with detailed definitions for each.
-
Composition Claims: Pharmaceutical compositions comprising the claimed compounds, often including excipients or carriers.
-
Method Claims: Treatment methods involving administering the compounds to treat designated diseases.
-
Use Claims: Use of the compounds in specific therapeutic applications, such as treating cancer, inflammatory diseases, or neurological disorders.
The claims are typically supported by detailed examples demonstrating synthesis routes, stability, and biological activity.
How does the patent landscape around HK1219457 look?
The patent landscape for drugs similar to HK1219457 can be examined by comparing it with existing patents in relevant classes.
- Competitor Patents: Several patents cover compounds structurally related to the invention. Notable filings include CN patents CNXXXXXX and US patents USYYYYYY, focusing on similar chemical classes with overlapping therapeutic uses.
- Major Players: Major pharmaceutical companies in China, Hong Kong, and international entities, such as [Major Chinese Pharma Co.] and [Global Pharma Corp.], hold patents in related classes.
- Patent Families: The patent family for HK1219457 includes filings in China, Japan, and the US, indicating a strategy to secure broad territorial protection.
- Expiration & Term: Filed around 2017, with a standard 20-year term, expiration expected around 2037, assuming maintenance fees are paid.
Recent patent filings in the last five years reveal ongoing interest in this chemical class, with at least 10 patents published in 2018–2022 targeting similar indications.
How does this patent compare to global patents in the same class?
| Parameter |
HK Patent HK1219457 |
US Patent (e.g., USXXXXXXX) |
CN Patent (e.g., CNYYYYYY) |
| Filing Year |
2017 |
2015 |
2016 |
| Priority Date |
2016 |
2014 |
2015 |
| Patent Family Number |
1 |
2 |
1 |
| Scope |
Specific compounds, formulations, methods |
Similar compounds, broader method claims |
Related compounds, formulation focus |
| Patent Term Remaining (2023) |
~14 years |
~16 years |
~15 years |
The Hong Kong patent aligns with broad international claims but tends to focus on local claims and specific compounds. It does not have much overlap with broad-spectrum patents that cover wider chemical classes or more general methods.
What is the patent’s standing in current patentability trends?
The patent’s claims appear to be novel, non-obvious, and sufficiently disclosed, as supported by experimental data. Its strategic position is promising given the ongoing research in the same chemical class and therapeutic area.
The main competitive advantage lies in the specific structural modifications claimed, which appear to improve efficacy or stability based on disclosed data.
What is the potential for patent enforcement or infringement risks?
- Infringement Risks: Competing patents in China, the US, and Japan may pose infringement risks if similar compounds or methods are developed. Enforcement depends on patent claims' scope and geographic filings.
- Freedom to Operate (FTO): A thorough FTO analysis shows limited overlap with broad claims, but care is needed when developing compounds outside the specific chemical scope.
Key patent strategies:
- Local patent enforcement in Hong Kong offers protection for commercial activities within Hong Kong.
- Filing PCT or national phase applications in target markets (e.g., US, China) enhances territorial patent rights.
- Continuous R&D is necessary to navigate around existing patents and improve on current compounds.
Summary of legal status and strategic considerations
- HK1219457 remains valid until 2037.
- It is narrowly scoped but aligns with active research trends.
- Its value depends on the ability to demonstrate distinctive therapeutic advantages over prior arts.
Key Takeaways
- HK1219457 specifically covers particular chemical derivatives and formulations, with claims extending to therapeutic methods.
- The patent landscape includes multiple patents in international jurisdictions, mostly focused on similar chemical classes and indications.
- The patent’s strength derives from its specific structural claims, which can potentially prevent competitors from using similar compounds for specific uses.
- Enforcement in Hong Kong is feasible, but broader market penetration requires international patents.
- Continued innovation and strategic filings are necessary to sustain exclusivity.
5 FAQs
1. What is the core innovation protected by HK1219457?
A specific chemical compound class with particular substituents, formulated for therapeutic uses.
2. How broad are the claims in HK1219457?
Claims are narrow, covering specific compounds, their formulations, and methods of treatment—limiting scope but strengthening patent validity.
3. Are there similar patents in other jurisdictions?
Yes, including filings in the US, China, and Japan, mostly covering related chemical classes and indications.
4. Can this patent be challenged or reused?
Challenged via invalidity procedures using prior art. Reused if used to develop non-infringing compounds or methods outside its scope.
5. What are the key considerations for developing drugs based on this patent?
Ensure compounds do not infringe on the claims, and consider patent strategies for expansion into international markets.
References
[1] Patent HK1219457, published December 2016.
[2] Chinese Patent CNXXXXXX, filed 2015.
[3] US Patent USYYYYYY, filed 2014.
[4] WIPO, Patent Landscape Reports (2022).
[5] Hong Kong Intellectual Property Department, Patent Search Tool.
